Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Octaplas Adult TTP Trial

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified November 2014 by Octapharma
Information provided by (Responsible Party):
Octapharma Identifier:
First received: September 2, 2013
Last updated: June 5, 2015
Last verified: November 2014
To assess and evaluate the safety of octaplas™ in comparison to standard plasma product (e.g., fresh frozen plasma (FFP) and other approved plasma products used within 24 hours of thawing) used in the treatment of TTP, in patients undergoing Therapeutic Plasma Exchange, with a special emphasis on the occurrence of thromboembolic events (TEEs).

Condition Intervention
Thrombotic Thrombocytopenic Purpura
Biological: Octaplas

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Post-Marketing Requirement Study to Evaluate the Safety and Efficacy of Octaplas™ in Patients With Thrombotic Thrombocytopenic Purpura With Special Emphasis on Monitoring the Occurrence of Thromboembolic Events

Resource links provided by NLM:

Further study details as provided by Octapharma:

Primary Outcome Measures:
  • The number of TEEs reported [ Time Frame: Up to 28 days followed by a 24 hour follow-up ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The frequency of TEEs reported [ Time Frame: Up to 28 days followed by a 24 hour follow-up ] [ Designated as safety issue: Yes ]
  • Investigator Responses to the efficacy rating scale [ Time Frame: Up to 28 days followed by a 24 hour follow-up ] [ Designated as safety issue: Yes ]
  • Number of Serious ADRs reported [ Time Frame: Up to 28 days followed by a 24 hour follow-up ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 120
Study Start Date: December 2015
Estimated Study Completion Date: August 2017
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patients receiving Octaplas for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures
Biological: Octaplas
standard plasma products
Patients receiving standard plasma products (e.g., FFP, etc) for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Adult patients undergoing Plasma exchange for Thrombotic Thrombocytopenic Purpura

Inclusion Criteria:

  1. Patient is a male or female at least 18 years of age or older.
  2. Patient has a diagnosis of TTP or suspicion of TTP that is planned on being treated with TPE within 3 days of study entry.
  3. Patient has thrombocytopenia (platelets < 100 x 10P9P/L).
  4. Patient is willing to give voluntary written informed consent before any study-related procedure is to be performed that is not part of standard medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.

Exclusion Criteria:

  1. Patient has a history of severe hypersensitivity reaction to plasma-derived products or to FFP.
  2. Patient has an already known IgA deficiency with documented antibodies against IgA.
  3. Patient is currently participating in an interventional clinical study or has participated during the past 1 month prior to study inclusion.
  4. Patient has severe deficiencies of Protein S.
  5. Patient has a history of TTP relapse.
  6. Patient received more than 1 treatment of plasma exchange or plasma infusion for current episode of TTP prior to randomization.
  7. Patient received treatment for TTP within previous 6 months.
  8. Patient is currently taking ACE-inhibitors.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01938404

Contact: Michael Eppolito, MBA

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Sponsors and Collaborators
  More Information

Responsible Party: Octapharma Identifier: NCT01938404     History of Changes
Other Study ID Numbers: LAS-214 
Study First Received: September 2, 2013
Last Updated: June 5, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Octapharma:
Plasma exchange
Thrombotic Thrombocytopenic Purpura

Additional relevant MeSH terms:
Purpura, Thrombocytopenic
Purpura, Thrombotic Thrombocytopenic
Blood Coagulation Disorders
Hematologic Diseases
Pathologic Processes
Skin Manifestations
Signs and Symptoms
Thrombotic Microangiopathies
Blood Platelet Disorders
Immune System Diseases
Thrombophilia processed this record on September 28, 2016